| scholarly article | Q13442814 |
| P50 | author | Oleh Hornykiewicz | Q85990 |
| P2093 | author name string | Yoshiaki Furukawa | |
| Mark Guttman | |||
| Stephen J Kish | |||
| Junchao Tong | |||
| Ali Rajput | |||
| Li-Jan Chang | |||
| P433 | issue | Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| serotonin | Q167934 | ||
| putamen | Q550934 | ||
| P304 | page(s) | 120-131 | |
| P577 | publication date | 2007-10-22 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease | |
| P478 | volume | 131 |
| Q64866418 | Q64866418 |
| Q39001069 | A Neurocomputational Model of the Effect of Cognitive Load on Freezing of Gait in Parkinson's Disease. |
| Q41860693 | A computational model of altered gait patterns in parkinson's disease patients negotiating narrow doorways. |
| Q42393827 | A marked contrast between serotonergic and dopaminergic changes in dopa-responsive dystonia |
| Q34094065 | A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions |
| Q36972794 | A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. |
| Q38223905 | Association between 5-HTTLPR polymorphism and Parkinson's disease: a meta analysis |
| Q64881160 | Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum. |
| Q48445004 | Biodistribution and Radiation Dosimetry of [18F]Mefway in Humans. |
| Q46326792 | Brain serotonin transporter in human methamphetamine users |
| Q36899059 | Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease |
| Q41510167 | Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study |
| Q38598375 | Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease |
| Q36316462 | Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits |
| Q89520027 | Chronic Systemic Inflammation Exacerbates Neurotoxicity in a Parkinson's Disease Model |
| Q41823908 | Circadian Clock Protein Content and Daily Rhythm of Locomotor Activity Are Altered after Chronic Exposure to Lead in Rat. |
| Q47952640 | Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. |
| Q37715032 | Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons |
| Q39557159 | Constitutive and Acquired Serotonin Deficiency Alters Memory and Hippocampal Synaptic Plasticity |
| Q37973611 | Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. |
| Q37396722 | Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation. |
| Q36271585 | Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial |
| Q37971293 | Depression in Parkinson disease--epidemiology, mechanisms and management. |
| Q36857900 | Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys |
| Q35038040 | Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia |
| Q36154790 | Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease |
| Q39075710 | Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease. |
| Q38827653 | Effects of Physical Rehabilitation Integrated with Rhythmic Auditory Stimulation on Spatio-Temporal and Kinematic Parameters of Gait in Parkinson's Disease. |
| Q47361475 | Effects of hypothyroidism on serotonin 1A receptors in the rat brain |
| Q53070835 | Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats. |
| Q36745645 | Efferent projections of neuropeptide Y-expressing neurons of the dorsomedial hypothalamus in chronic hyperphagic models |
| Q36883134 | Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism |
| Q52558618 | Exploring diagnosis and imaging biomarkers of Parkinson's disease via iterative canonical correlation analysis based feature selection. |
| Q42872557 | Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. |
| Q50080406 | Fractionating the Neurocognitive Mechanisms Underlying Working Memory: Independent Effects of Dopamine and Parkinson's Disease. |
| Q43166005 | High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. |
| Q89533763 | High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort |
| Q35324977 | Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia |
| Q52665081 | In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease. |
| Q34018843 | In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease |
| Q38199670 | Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. |
| Q58795485 | Investigation of Behavioral Dysfunctions Induced by Monoamine Depletions in a Mouse Model of Parkinson's Disease |
| Q55287139 | Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. |
| Q89521076 | Is serotonin pathology a good biomarker in vivo for early Parkinson's disease? |
| Q97519880 | KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson's Disease |
| Q92445892 | L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning |
| Q36087200 | L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease |
| Q37486030 | L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum |
| Q43517732 | Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. |
| Q46153193 | Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. |
| Q40379397 | Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs |
| Q24040262 | Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease |
| Q42224924 | Mathematical insights into the effects of levodopa |
| Q46048460 | Modeling task-specific manifestations of serotonin in basal ganglia using risk-based decision making |
| Q36724965 | Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease |
| Q35165280 | Monoamine reuptake inhibitors in Parkinson's disease |
| Q44523798 | Monoaminergic Modulation of Motor Cortex Function |
| Q43257873 | Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression |
| Q38101499 | Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology |
| Q34181738 | Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease |
| Q91710418 | Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses |
| Q38126817 | Non-dopaminergic treatments for motor control in Parkinson's disease |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q35013240 | Noradrenaline and Parkinson's disease |
| Q30493158 | Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease |
| Q58913404 | Parkinson's disease and sleep/wake disturbances |
| Q26824184 | Parkinson's disease: gene therapies |
| Q35951218 | Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice |
| Q37929598 | Positron emission tomography neuroimaging in Parkinson's disease |
| Q28581025 | Postnatal changes in tryptophan hydroxylase and serotonin transporter immunoreactivity in multiple brainstem nuclei of the rat: implications for a sensitive period |
| Q48121057 | Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter |
| Q21129423 | Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications |
| Q36743112 | Presynaptic serotonergic gating of the subthalamonigral glutamatergic projection |
| Q36691830 | Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration |
| Q60907864 | Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia |
| Q35893872 | Retracted: Influences of Chronic Mild Stress Exposure on Motor, Non-Motor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP/Probenecid Induced Neurotoxicity in Mice |
| Q34299945 | Risk of sleep-disordered breathing in Parkinson's disease |
| Q39407055 | SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias |
| Q35875725 | SPECT molecular imaging in Parkinson's disease |
| Q29994860 | Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease |
| Q52332824 | Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. |
| Q53188615 | Serotonergic dysfunction in Parkinson's disease and its relevance to disability. |
| Q55050175 | Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. |
| Q37536347 | Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD |
| Q37602233 | Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients |
| Q38881337 | Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies |
| Q36680671 | Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice |
| Q41902470 | Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy |
| Q36798864 | Serotonin2C Receptors and the Motor Control of Oral Activity |
| Q30621723 | Social behavioral changes in MPTP-treated monkey model of Parkinson's disease |
| Q28485942 | Striatal glutamate release in L-DOPA-induced dyskinetic animals |
| Q37509682 | Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease |
| Q35942601 | Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms |
| Q38562348 | The Vulnerable Ventral Tegmental Area in Parkinson's Disease |
| Q41963193 | The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats |
| Q35813427 | The aqueous extract of Albizia adianthifolia leaves attenuates 6-hydroxydopamine-induced anxiety, depression and oxidative stress in rat amygdala. |
| Q33724698 | The neurobiological basis of cognitive impairment in Parkinson's disease |
| Q47400257 | The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease |
| Q28727519 | The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study |
| Q48372783 | The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. |
| Q38118061 | The serotonergic system in motor and non-motor manifestations of Parkinson's disease |
| Q64317860 | Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery |
| Q33625060 | Treadmill exercise alleviates depressive symptoms in rotenone-induced Parkinson disease rats |
| Q34482196 | Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease |
| Q41547990 | Uncovering the underlying mechanisms and whole-brain dynamics of deep brain stimulation for Parkinson's disease |
| Q38434699 | What Gene Mutations Affect Serotonin in Mice? |
| Q27313863 | α-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter |
Search more.